Research tools are urgently needed to elucidate the specificities of NMO and MS due to their clinical similarity at the early stage of the diseases. Herein, using high-field-strength MRI we characterized the optic nerve and spinal cord lesions in 2D2 tg mice (MOG 35-55 specific TCR 
Introduction
Neuromyelitis Optica (NMO) also known as Devic's disease, is the co-occurrence of optic neuritis and myelitis (Cree et al., 2002) . The clinical presentation of NMO is very similar to multiple sclerosis (MS), another neuroinflammatory disease (Sinnecker et al., 2012) , and due to their similarities, some NMO patients have been misdiagnosed. Recent research however has begun to identify NMO as its own specific disease (Cree et al., 2002; Wingerchuk and Weinshenker, 2003; Kinoshita et al., 2009; Pfueller and Paul, 2011) . NMO has been shown to have inflammatory foci that localize specifically to the optic nerve and spinal cord (Wingerchuk et al., 1999; Cree et al., 2002; Lucchinetti et al., 2002; Wingerchuk and Weinshenker, 2003) . Unlike in MS (Sinnecker et al., 2012) , there are very limited lesions in the brain of NMO. An early and correct diagnosis of NMO is imperative due to the poorer prognosis of the disease in comparison to MS. There is also a different treatment regiment for NMO as compared to MS, so early detection and correct treatments are imperative (Mandler et al., 1993; Wingerchuk and Weinshenker, 2005; Wingerchuk et al., 2006) . Recently, serum reactivity that targets aquaporin-4 (AQP4) has been used to distinguish NMO from MS patients (Jarius and Wildemann, 2010) . This antibody, AQP4-Ab also known as NMO-IgG, is detectable in 60-90% of patients with NMO and has been used as one of the criteria for diagnosing NMO (Lennon et al., 2005; Papadopoulos and Verkman, 2012) . However, the pathology of NMO remains largely unknown, and a precise diagnosis is urgently needed.
Animal models that have distinct features that closely resemble that of NMO are important tools to study the disease. Currently, there have been steps taken to develop NMO animal models that utilize the antibody AQP4 as a way to induce NMO. Some of those emerging models include transferring NMO patient's sera to rats to induce NMO and an ex vivo spinal cord slice model. However, there are limitations to these models. The use of spinal cord slices provides little information about the systemic effects of the disease. The NMO patient sera model induces experimental autoimmune encephalomyelitis (EAE) first, and then introduces the patient's IgG, thus the effects of sera alone are lost (Kinoshita et al., 2009; Zhang et al., 2011) . Finally, by using a primary anti-AQP4 antibody for inducing disease, these models can not address the 10-40% of NMO patients that are AQP4 sera negative.
Kuchroo's group developed a TCR (T cell receptor) transgenic mouse (2D2 tg ), with the majority of CD4 cells recognizing a myelin antigen myelin oligodendrocyte glycoprotein (MOG) derived from an MS patient who showed isolated optic neuritis in the absence of clinical or histological signs of EAE (Bettelli et al., 2003 
